Human Insulin Market

Key Highlights of the report

How are the major segments performing in the Human Insulin Market?

• In 2022, the insulin analogs & biosimilar drugs segment accounted for the largest global human insulin market revenue share. Its dominance can be attributed to increased insulin efficacy and fewer side effects, such as hypoglycemic episodes and weight gain, compared to conventional therapy.
• The pens delivery devices segment held a significant global human insulin market revenue share in 2022 due to the commercialization of cutting-edge human insulin pens and the substantial medical reimbursement scenarios provided for human insulin pens across mature markets.
• The delivery devices product type segment held most of the human insulin market share in 2022. The segment is expected to be driven by factors such as patent protection and growing preference due to long-term effects.
• In 2022, the Novorapid & Novolog brand segment controlled most of the human insulin market owing to the wider global popularity and minimally invasive procedure.

What is the Market Size of Human Insulin regarding value?

The global human insulin market is anticipated to grow at a substantial CAGR of 3.2% in the upcoming years. The Global Human Insulin industry was estimated to be worth USD 18.8 billion in 2022 and was expected to be worth USD 23.43 billion by 2028.

Which region dominated the human insulin market?

The increased prevalence of diabetes and technological developments in efficient insulin delivery have led to North America’s dominance of the global human insulin market. Some factors driving North America’s insulin drug market include the strong presence of major insulin manufacturers, intense competition among companies, and the rising prevalence of type 1 diabetes. For instance, 1.6 million Americans, including 187,000 children and teenagers, have type-1 diabetes, according to the American Diabetes Association (ADA). Moreover, the rising price of insulin in the United States over the last decade has allowed the North American market to capture a sizable portion of the overall market. Eli Lilly & Company, Novo Nordisk A/S, and Sanofi are some of the significant companies currently active in this region.

How is US Market Performing in the Human Insulin Market?

North America, particularly the United States, dominates the global human insulin market, owing to the region’s high prevalence of diabetes due to a sedentary lifestyle. The United States is expected to grow significantly during the projection period due to factors such as the high prevalence of obesity and increasing public awareness of the need for diabetes care in the region. For instance, the Centers for Disease Control and Prevention (CDC) estimates that about 100 million Americans have diabetes. The prevalence of diabetes and unstable blood sugar levels among younger generations is also significant. The increase in young diabetics is expected to fuel human insulin market expansion over the forecast period. Technological advancements and developments in the formulation are other important factors supporting the expansion of the human insulin market in the United States.

How is the economy impacting global human insulin growth?

Insulin prices have risen at an inexplicably faster rate than inflation. The emergence of COVID-19 has primarily hampered insulin demand as fewer patients seek diabetes treatment. In addition, major market players saw a sharp drop in revenue due to the COVID-19 pandemic and supply chain disruption brought on by the conflict between the United States and Ukraine. The market participants noticed a sharp drop in revenue produced in 2021. For instance, Sanofi reported a drop in revenue from insulin products from 2020 to 2021 of about -7.9%. The human insulin market is characterized by inequitable pricing, with emerging economies needing more access to human insulin.

What is the competitive environment of the human insulin market?

Novo Nordisk A/S, Sanofi, and Eli Lilly & Company are current global human insulin market leaders in revenue. Novo Nordisk A/S has captured the largest human insulin market share and is expected to maintain its position due to the company’s increasing partnership strategies and technological innovations in drug discovery. Furthermore, significant investments in research activities to build a portfolio of superior treatment solutions have enabled the company to maintain a market leadership position. For instance, Novo Nordisk A/S procured Dicerna Pharmaceuticals in November 2021, including the ribonucleic acid interference (RNAi) platform from Dicerna and Novo Nordisk’s research technology platforms, which are utilized across all of Novo Nordisk’s therapeutic areas.

Executive Summary

What are the key trends in the Human Insulin market?

• Growing prevalence of diabetes across the globe: Diabetes is one of the world’s fastest-growing chronic diseases. Its prevalence has steadily increased over the last few decades. Obesity and sedentary lifestyles are major contributors to the global rise in diabetes. Diabetes is becoming more common in low- and middle-income countries, where three out of every four adults have the disease. As per the International Diabetes Federation (IDF), approximately 643 million people will have diabetes by 2030 and 783 million by 2045. Besides, the growing geriatric and obese populations are driving growth. Overweight people are more likely to develop type 2 diabetes. In 2020, 1.9 billion adults, or 39% of the population in that age group, were reported to be overweight, according to the WHO.

What are all the technical developments in the human insulin market?

The increased use of insulin administration delivery devices is a significant trend in the human insulin industry. Technological advancements in insulin-delivery devices have prompted various industry participants to invest in developing effective insulin-delivery devices. For instance, the Food and Drug Administration in the United States approved Medtronic’s MiniMed 670 G in September 2017. It is the first closed-loop arbitrary pancreas hybrid device created to regulate blood sugar levels and automatically change basal insulin doses in patients with type I diabetes (USFDA). Research and development spending in the insulin market is increasing yearly as scientists work to develop the best drug molecule for patient use, reduce side effects to the absolute minimum, and boost efficacy.

Which are the key investments by the human insulin market players?

Increased investment in diabetes research is expected to propel the global human insulin market forward. Various government and private research organizations are involved in R&D activities to develop advanced diabetes care treatments to increase the effectiveness of human insulin, reduce diabetes burden, and reduce the risk of diabetes-related disorders such as kidney disease, blindness, strokes, heart attacks, or limb loss. Additionally, key players invest in mergers & acquisitions to expand geographically, form strategic alliances, and form partnerships in developing and prosperous regions. For example, in February 2022, Biocon announced that it had acquired Viatris’ biosimilar portfolio for USD 3.335 billion. This acquisition expanded Biocon’s biologic drugs product portfolio and increased revenue.

Some major players in the human insulin market are Novo Nordisk A/S (Denmark), Eli Lilly & Company (US), Boston Scientific Corporation (US), Sanofi (France), Boehringer Ingelheim International GmbH (Germany), Biocon (India), Tonghua Dongbao Pharmaceutical (China), Julphar (UAE), and Wockhardt (India).

What are the Major Driving Factors for the Human Insulin Market?

A growing number of people with diabetes, increased exposure to the main diabetes risk factors, rising consumer demand for human insulin analogs, emerging technological advancements in the field of insulin delivery devices, and increased favorable medical reimbursements are all expected to contribute to the growth of the market for human insulin during the forecast period. Some of the factors anticipated to boost the growth of the insulin market include an increase in the number of diabetic patients, a rise in the prevalence of obesity among older adults, an increase in public awareness of the benefits of insulin, and government initiatives to improve healthcare.

What are the Major Risks for the Human Insulin Market?

Strict regulatory requirements for product approval, rising insulin costs, a lack of favorable insurance policies, and increased competition among existing manufacturers will slow the growth rate of the human insulin market.

Which are the key drugs in the human insulin market?

Analog insulin dominated the global human insulin market in 2022, owing to its increasing advantages over traditional human insulin. Analog insulin has better glycemic control and therapy adherence, according to numerous published articles and whitepapers. In addition, compared to conventional products, it does not carry as great a risk of hypoglycemia. Analog insulins also have a quick and consistent rate of action, according to Diabetes.co.uk. As a result, analog insulin has seen increased demand over the last five years. In addition, the recent introduction of generic insulin is expected to drive the growth of the analog insulin market. Novo Nordisk A/S introduced the generic versions of NovoLog and NovoLog mix in January 2020; both are offered at an approximately 50% lower price than the brand-name versions.

How is the human insulin market performing in regions?

The Asia Pacific region is expected to grow the fastest in the global human insulin market projection period, owing to factors such as rising geriatric and target populations, an increasing number of collaborations for biosimilar development, global coverage of key players, and active participation of government and non-profits organizations in the market space. This may be attributed to the expansion of R&D activities carried out by different organizations and the expansion of regional government initiatives. Besides, health-awareness campaigns and scientific conferences to combat this disease fuel regional market growth. The market’s growth was also aided by the region’s top anti-diabetic drug manufacturers and the fact that more than 70% of people with diabetes worldwide reside in developing nations.

What is the regulatory landscape for the human insulin market?

Insulin delivery system formulation advancements are being developed, and their release is expected to propel the global human insulin market during the forecast period. For example, the FDA approved the interoperable device Control-IQ from Tandem Diabetes Care for marketing in the United States in December 2019. It is an algorithm for automatically administering insulin compatible with other devices that can communicate with it. The new rapid-acting insulin from Lyumjev, Eli Lilly & Company was given FDA approval in June 2020 to help adults with type 1 and type 2 diabetes maintain better glycemic control. As a result, such regulatory scenarios will bolster future human insulin market expansion.

What are the major players planning for the future of the human insulin market?

The market for human insulin is experiencing a large influx of new products. Manufacturers are focusing on developing distinctive insulin products with higher effectiveness to grow their market share and support the expansion of the human insulin industry. For instance, Eli Lilly and Company’s Mounjaro injection, which aids patients with type 2 diabetes in improving their glycemic control, received approval in May 2022.

Segmentation of Global Human Insulin Market-

Global Human Insulin Market – By Product Type

• Drugs
• Delivery Devices

Global Human Insulin Market – By Drugs

• Insulin Analogs & Biosimilars
  • Rapid-acting
  • Long-acting
  • Premixed
• Human Insulin Biologics
  • Short-acting
  • Intermediate-acting
  • Premixed

Global Human Insulin Market – By Delivery Devices

• Pens
  • Reusable
  • Disposable
• Pen Needles
  • Standard
  • Safety
• Syringes
• Others

Global Human Insulin Market – By Brand

• Human Insulin Biologics
  • Humulin
  • Insuman
• Insulin Analogs & Biosimilars
  • Lantus
  • Novorapid & Novolog
  • Humalog
  • Others

Global Human Insulin Market – By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Introduction
1.5. Market Research Scope

2. Executive Summary
2.1. Market Snapshot: Global Human Insulin Market
2.2. Global Human Insulin Market, By Product Type
2.3. Global Human Insulin Market, By Drugs
2.4. Global Human Insulin Market, By Delivery Devices
2.5. Global Human Insulin Market, By Brand
2.6. Global Human Insulin Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Human Insulin Market Value, 2017-2030, (US$ Bn)
3.1.2. Y-o-Y Growth Trend Analysis
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Major Industry Challenges
3.3. Growth and Development Patterns
3.4. Investment Feasibility Analysis
3.5. Market Opportunity Analysis
3.5.1. Product Type
3.5.2. Drugs
3.5.3. Delivery Devices
3.5.4. Brand
3.5.5. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Key Market Trends
4.3.1. Demand Side Trends
4.3.2. Supply Side Trends
4.4. Value Chain Analysis
4.5. Technology Analysis
4.6. Analysis and Recommendations
4.7. Marketing Strategy Analysis
4.7.1. Direct Marketing
4.7.2. Indirect Marketing
4.7.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2022
5.1. Company Market Share of Key Players, 2022
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. Economic Impact Analysis
6.1. Recession Impact
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Latin America
6.1.5. Middle East and Africa
6.2. Ukraine-Russia War Impact
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. COVID-19 Impact Analysis
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Latin America
6.3.5. Middle East and Africa

7. Global Human Insulin Market
7.1. Global Human Insulin Market, by Product Type, 2017-2030(US$ Bn)
7.1.1. Overview
7.1.2. Global Human Insulin Market, By Product Type, 2022 vs 2030 (in%)
7.1.3. Global Human Insulin Market, By Drugs, 2017-2030 (US$ Bn)
7.1.4. Global Human Insulin Market, By Delivery Devices, 2017-2030 (US$ Bn)
7.2. Global Human Insulin Market, by Drugs, 2017-2030(US$ Bn)
7.2.1. Overview
7.2.2. Global Human Insulin Market, By Drugs, 2022 vs 2030 (in%)
7.2.3. Global Human Insulin Market, By Insulin Analogs & Biosimilars, 2017-2030 (US$ Bn)
7.2.4. Global Human Insulin Market, By Human Insulin Biologics, 2017-2030 (US$ Bn)
7.3. Global Human Insulin Market, by Delivery Devices, 2017-2030(US$ Bn)
7.3.1. Overview
7.3.2. Global Human Insulin Market, By Delivery Devices, 2022 vs 2030 (in%)
7.3.3. Global Human Insulin Market, By Pens, 2017-2030 (US$ Bn)
7.3.4. Global Human Insulin Market, By Pen Needles, 2017-2030 (US$ Bn)
7.3.5. Global Human Insulin Market, By Syringes, 2017-2030 (US$ Bn)
7.3.6. Global Human Insulin Market, By Others, 2017-2030 (US$ Bn)
7.4. Global Human Insulin Market, by Brand, 2017-2030(US$ Bn)
7.4.1. Overview
7.4.2. Global Human Insulin Market, By Brand, 2022 vs 2030 (in%)
7.4.3. Global Human Insulin Market, By Humulin, 2017-2030 (US$ Bn)
7.4.4. Global Human Insulin Market, By Insuman, 2017-2030 (US$ Bn)
7.4.5. Global Human Insulin Market, By Lantus, 2017-2030 (US$ Bn)
7.4.6. Global Human Insulin Market, By Novorapid & Novolog, 2017-2030 (US$ Bn)
7.4.7. Global Human Insulin Market, By Humalog, 2017-2030 (US$ Bn)
7.4.8. Global Human Insulin Market, By Others, 2017-2030 (US$ Bn)

8. North America Human Insulin Market Analysis
8.1. North America Human Insulin Market, by Product Type, 2017-2030(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Human Insulin Market, by Drugs, 2017-2030(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Human Insulin Market, by Delivery Devices, 2017-2030(US$ Bn)
8.3.1. Overview
8.3.2. SRC Analysis
8.4. North America Human Insulin Market, by Brand, 2017-2030(US$ Bn)
8.4.1. Overview
8.4.2. SRC Analysis
8.5. North America Human Insulin Market, by Country, 2017-2030 (US$ Bn)
8.5.1. U.S.
8.5.1.1. U.S. Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
8.5.1.2. U.S. Human Insulin, By Product Type, 2017-2030 (US$ Bn)
8.5.1.3. U.S. Human Insulin, By Drugs, 2017-2030 (US$ Bn)
8.5.1.4. U.S. Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
8.5.1.5. U.S. Human Insulin, By Brand, 2017-2030 (US$ Bn)
8.5.2. Canada
8.5.2.1. Canada Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
8.5.2.2. Canada Human Insulin, By Product Type, 2017-2030 (US$ Bn)
8.5.2.3. Canada Human Insulin, By Drugs, 2017-2030 (US$ Bn)
8.5.2.4. Canada Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
8.5.2.5. Canada Human Insulin, By Brand, 2017-2030 (US$ Bn)

9. Europe Human Insulin Market Analysis
9.1. Europe Human Insulin Market, by Product Type, 2017-2030(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Human Insulin Market, by Drugs, 2017-2030(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Human Insulin Market, by Delivery Devices, 2017-2030(US$ Bn)
9.3.1. Overview
9.3.2. SRC Analysis
9.4. Europe Human Insulin Market, by Brand, 2017-2030(US$ Bn)
9.4.1. Overview
9.4.2. SRC Analysis
9.5. Europe Human Insulin Market, by Country, 2017-2030 (US$ Bn)
9.5.1. Germany
9.5.1.1. Germany Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.5.1.2. Germany Human Insulin, By Product Type, 2017-2030 (US$ Bn)
9.5.1.3. Germany Human Insulin, By Drugs, 2017-2030 (US$ Bn)
9.5.1.4. Germany Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
9.5.1.5. Germany Human Insulin, By Brand, 2017-2030 (US$ Bn)
9.5.2. France
9.5.2.1. France Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.5.2.2. France Human Insulin, By Product Type, 2017-2030 (US$ Bn)
9.5.2.3. France Human Insulin, By Drugs, 2017-2030 (US$ Bn)
9.5.2.4. France Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
9.5.2.5. France Human Insulin, By Brand, 2017-2030 (US$ Bn)
9.5.3. UK
9.5.3.1. UK Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.5.3.2. UK Human Insulin, By Product Type, 2017-2030 (US$ Bn)
9.5.3.3. UK Human Insulin, By Drugs, 2017-2030 (US$ Bn)
9.5.3.4. UK Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
9.5.3.5. UK Human Insulin, By Brand, 2017-2030 (US$ Bn)
9.5.4. Italy
9.5.4.1. Italy Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.5.4.2. Italy Human Insulin, By Product Type, 2017-2030 (US$ Bn)
9.5.4.3. Italy Human Insulin, By Drugs, 2017-2030 (US$ Bn)
9.5.4.4. Italy Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
9.5.4.5. Italy Human Insulin, By Brand, 2017-2030 (US$ Bn)
9.5.5. Spain
9.5.5.1. Spain Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.5.5.2. Spain Human Insulin, By Product Type, 2017-2030 (US$ Bn)
9.5.5.3. Spain Human Insulin, By Drugs, 2017-2030 (US$ Bn)
9.5.5.4. Spain Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
9.5.5.5. Spain Human Insulin, By Brand, 2017-2030 (US$ Bn)
9.5.6. Rest of Europe
9.5.6.1. Rest of Europe Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
9.5.6.2. Rest of Europe Human Insulin, By Product Type, 2017-2030 (US$ Bn)
9.5.6.3. Rest of Europe Human Insulin, By Drugs, 2017-2030 (US$ Bn)
9.5.6.4. Rest of Europe Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
9.5.6.5. Rest of Europe Human Insulin, By Brand, 2017-2030 (US$ Bn)

10. Asia Pacific Human Insulin Market Analysis
10.1. Asia Pacific Human Insulin Market, by Product Type, 2017-2030(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Human Insulin Market, by Drugs, 2017-2030(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Human Insulin Market, by Delivery Devices, 2017-2030(US$ Bn)
10.3.1. Overview
10.3.2. SRC Analysis
10.4. Asia Pacific Human Insulin Market, by Brand, 2017-2030(US$ Bn)
10.4.1. Overview
10.4.2. SRC Analysis
10.5. Asia Pacific Human Insulin Market, by Country, 2017-2030 (US$ Bn)
10.5.1. China
10.5.1.1. China Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.5.1.2. China Human Insulin, By Product Type, 2017-2030 (US$ Bn)
10.5.1.3. China Human Insulin, By Drugs, 2017-2030 (US$ Bn)
10.5.1.4. China Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
10.5.1.5. China Human Insulin, By Brand, 2017-2030 (US$ Bn)
10.5.2. Japan
10.5.2.1. Japan Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.5.2.2. Japan Human Insulin, By Product Type, 2017-2030 (US$ Bn)
10.5.2.3. Japan Human Insulin, By Drugs, 2017-2030 (US$ Bn)
10.5.2.4. Japan Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
10.5.2.5. Japan Human Insulin, By Brand, 2017-2030 (US$ Bn)
10.5.3. India
10.5.3.1. India Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.5.3.2. India Human Insulin, By Product Type, 2017-2030 (US$ Bn)
10.5.3.3. India Human Insulin, By Drugs, 2017-2030 (US$ Bn)
10.5.3.4. India Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
10.5.3.5. India Human Insulin, By Brand, 2017-2030 (US$ Bn)
10.5.4. South Korea
10.5.4.1. South Korea Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.5.4.2. South Korea Human Insulin, By Product Type, 2017-2030 (US$ Bn)
10.5.4.3. South Korea Human Insulin, By Drugs, 2017-2030 (US$ Bn)
10.5.4.4. South Korea Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
10.5.4.5. South Korea Human Insulin, By Brand, 2017-2030 (US$ Bn)
10.5.5. South-East Asia
10.5.5.1. South-East Asia Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.5.5.2. South-East Asia Human Insulin, By Product Type, 2017-2030 (US$ Bn)
10.5.5.3. South-East Asia Human Insulin, By Drugs, 2017-2030 (US$ Bn)
10.5.5.4. South-East Asia Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
10.5.5.5. South-East Asia Human Insulin, By Brand, 2017-2030 (US$ Bn)
10.5.6. Rest of Asia Pacific
10.5.6.1. Rest of Asia Pacific Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
10.5.6.2. Rest of Asia Pacific Human Insulin, By Product Type, 2017-2030 (US$ Bn)
10.5.6.3. Rest of Asia Pacific Human Insulin, By Drugs, 2017-2030 (US$ Bn)
10.5.6.4. Rest of Asia Pacific Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
10.5.6.5. Rest of Asia Pacific Human Insulin, By Brand, 2017-2030 (US$ Bn)

11. Latin America Human Insulin Market Analysis
11.1. Latin America Human Insulin Market, by Product Type, 2017-2030(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Human Insulin Market, by Drugs, 2017-2030(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Human Insulin Market, by Delivery Devices, 2017-2030(US$ Bn)
11.3.1. Overview
11.3.2. SRC Analysis
11.4. Latin America Human Insulin Market, by Brand, 2017-2030(US$ Bn)
11.4.1. Overview
11.4.2. SRC Analysis
11.5. Latin America Human Insulin Market, by Country, 2017-2030 (US$ Bn)
11.5.1. Brazil
11.5.1.1. Brazil Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.5.1.2. Brazil Human Insulin, By Product Type, 2017-2030 (US$ Bn)
11.5.1.3. Brazil Human Insulin, By Drugs, 2017-2030 (US$ Bn)
11.5.1.4. Brazil Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
11.5.1.5. Brazil Human Insulin, By Brand, 2017-2030 (US$ Bn)
11.5.2. Mexico
11.5.2.1. Mexico Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.5.2.2. Mexico Human Insulin, By Product Type, 2017-2030 (US$ Bn)
11.5.2.3. Mexico Human Insulin, By Drugs, 2017-2030 (US$ Bn)
11.5.2.4. Mexico Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
11.5.2.5. Mexico Human Insulin, By Brand, 2017-2030 (US$ Bn)
11.5.3. Rest of Latin America
11.5.3.1. Rest of Latin America Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
11.5.3.2. Rest of Latin America Human Insulin, By Product Type, 2017-2030 (US$ Bn)
11.5.3.3. Rest of Latin America Human Insulin, By Drugs, 2017-2030 (US$ Bn)
11.5.3.4. Rest of Latin America Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
11.5.3.5. Rest of Latin America Human Insulin, By Brand, 2017-2030 (US$ Bn)

12. Middle East and Africa Human Insulin Market Analysis
12.1. Middle East and Africa Human Insulin Market, by Product Type, 2017-2030(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Human Insulin Market, by Drugs, 2017-2030(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Human Insulin Market, by Delivery Devices, 2017-2030(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Middle East and Africa Human Insulin Market, by Brand, 2017-2030(US$ Bn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. Middle East and Africa Human Insulin Market, by Country, 2017-2030 (US$ Bn)
12.5.1. GCC Countries
12.5.1.1. GCC Countries Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.5.1.2. GCC Countries Human Insulin, By Product Type, 2017-2030 (US$ Bn)
12.5.1.3. GCC Countries Human Insulin, By Drugs, 2017-2030 (US$ Bn)
12.5.1.4. GCC Countries Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
12.5.1.5. GCC Countries Human Insulin, By Brand, 2017-2030 (US$ Bn)
12.5.2. South Africa
12.5.2.1. South Africa Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.5.2.2. South Africa Human Insulin, By Product Type, 2017-2030 (US$ Bn)
12.5.2.3. South Africa Human Insulin, By Drugs, 2017-2030 (US$ Bn)
12.5.2.4. South Africa Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
12.5.2.5. South Africa Human Insulin, By Brand, 2017-2030 (US$ Bn)
12.5.3. Rest of Middle East and Africa
12.5.3.1. Rest of Middle East and Africa Human Insulin Market Estimates and Forecast, 2017-2030 (US$ Bn)
12.5.3.2. Rest of Middle East and Africa Human Insulin, By Product Type, 2017-2030 (US$ Bn)
12.5.3.3. Rest of Middle East and Africa Human Insulin, By Drugs, 2017-2030 (US$ Bn)
12.5.3.4. Rest of Middle East and Africa Human Insulin, By Delivery Devices, 2017-2030 (US$ Bn)
12.5.3.5. Rest of Middle East and Africa Human Insulin, By Brand, 2017-2030 (US$ Bn)

13. Company Profiles
13.1. Novo Nordisk A/S (Denmark)
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2022)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Eli Lilly & Company (US)
13.3. Boston Scientific Corporation (US)
13.4. Sanofi (France)
13.5. Boehringer Ingelheim International GmbH (Germany)
13.6. Biocon (India)
13.7. Tonghua Dongbao Pharmaceutical (China)
13.8. Julphar (UAE)
13.9. Wockhardt (India)
13.10. Others

List of Figures
FIG. 1 Global Human Insulin Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Human Insulin Market Segmentation
FIG. 4 Global Human Insulin Market, by Product Type, 2022 (US$ Bn)
FIG. 5 Global Human Insulin Market, by Drugs, 2022 (US$ Bn)
FIG. 6 Global Human Insulin Market, by Delivery Devices, 2022 (US$ Bn)
FIG. 7 Global Human Insulin Market, by Brand, 2022 (US$ Bn)
FIG. 8 Global Human Insulin Market, by Geography, 2022 (US$ Bn)
FIG. 9 Attractive Investment Proposition, by Product Type, 2022
FIG. 10 Attractive Investment Proposition, by Drugs, 2022
FIG. 11 Attractive Investment Proposition, by Delivery Devices, 2022
FIG. 12 Attractive Investment Proposition, by Brand, 2022
FIG. 13 Attractive Investment Proposition, by Geography, 2022
FIG. 14 Global Market Share Analysis of Key Human Insulin Market Manufacturers, 2022
FIG. 15 Global Market Positioning of Key Human Insulin Market Manufacturers, 2022
FIG. 16 Global Human Insulin Market Value Contribution, By Product Type, 2022 & 2030 (Value %)
FIG. 17 Global Human Insulin Market, by Drugs, Value, 2017-2030 (US$ Bn)
FIG. 18 Global Human Insulin Market, by Delivery Devices, Value, 2017-2030 (US$ Bn)
FIG. 19 Global Human Insulin Market Value Contribution, By Drugs, 2022 & 2030 (Value %)
FIG. 20 Global Human Insulin Market, by Insulin Analogs & Biosimilars, Value, 2017-2030 (US$ Bn)
FIG. 21 Global Human Insulin Market, by Human Insulin Biologics, Value, 2017-2030 (US$ Bn)
FIG. 22 Global Human Insulin Market Value Contribution, By Delivery Devices, 2022 & 2030 (Value %)
FIG. 23 Global Human Insulin Market, by Pens, Value, 2017-2030 (US$ Bn)
FIG. 24 Global Human Insulin Market, by Pen Needles, Value, 2017-2030 (US$ Bn)
FIG. 25 Global Human Insulin Market, by Syringes, Value, 2017-2030 (US$ Bn)
FIG. 26 Global Human Insulin Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 27 Global Human Insulin Market Value Contribution, By Brand, 2022 & 2030 (Value %)
FIG. 28 Global Human Insulin Market, by Humulin, Value, 2017-2030 (US$ Bn)
FIG. 29 Global Human Insulin Market, by Insuman, Value, 2017-2030 (US$ Bn)
FIG. 30 Global Human Insulin Market, by Lantus, Value, 2017-2030 (US$ Bn)
FIG. 31 Global Human Insulin Market, by Novorapid & Novolog, Value, 2017-2030 (US$ Bn)
FIG. 32 Global Human Insulin Market, by Humalog, Value, 2017-2030 (US$ Bn)
FIG. 33 Global Human Insulin Market, by Others, Value, 2017-2030 (US$ Bn)
FIG. 34 U.S. Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 35 Canada Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 36 Germany Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 37 France Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 38 U.K. Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 39 Italy Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 40 Spain Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 41 Rest of Europe Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 42 China Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 43 Japan Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 44 India Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 45 South Korea Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 46 Southeast Asia Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 47 Rest of Asia Pacific Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 48 Latin America Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 49 Brazil Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 50 Mexico Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 51 Rest of Latin America Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 52 Middle East & Africa Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 53 GCC Countries Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 54 South Africa Human Insulin Market, 2017-2030 (US$ Bn)
FIG. 55 Rest of Middle East and Africa Human Insulin Market, 2017-2030 (US$ Bn)

List of Tables
TABLE 1 Market Snapshot: Global Human Insulin Market
TABLE 2 Global Human Insulin Market, by Competitive Benchmarking, 2022
TABLE 3 Global Human Insulin Market, by Geographical Presence Analysis, 2022
TABLE 4 Global Human Insulin Market, by Key Strategies Analysis, 2022
TABLE 5 Global Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 6 Global Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 7 Global Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 8 Global Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 9 Global Human Insulin Market, by Geography, 2017-2030 (US$ Bn)
TABLE 10 North America Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 11 North America Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 12 North America Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 13 North America Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 14 North America Human Insulin Market, by Country, 2017-2030 (US$ Bn)
TABLE 15 US Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 16 US Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 17 US Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 18 US Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 19 Canada Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 20 Canada Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 21 Canada Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 22 Canada Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 23 Europe Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 24 Europe Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 25 Europe Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 26 Europe Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 27 Europe Human Insulin Market, by Country, 2017-2030 (US$ Bn)
TABLE 28 Germany Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 29 Germany Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 30 Germany Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 31 Germany Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 32 France Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 33 France Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 34 France Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 35 France Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 36 UK Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 37 UK Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 38 UK Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 39 UK Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 40 Italy Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 41 Italy Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 42 Italy Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 43 Italy Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 44 Spain Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 45 Spain Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 46 Spain Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 47 Spain Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 48 Rest of Europe Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 49 Rest of Europe Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 50 Rest of Europe Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 51 Rest of Europe Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 52 Asia Pacific Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 53 Asia Pacific Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 54 Asia Pacific Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 55 Asia Pacific Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 56 Asia Pacific Human Insulin Market, by Country, 2017-2030 (US$ Bn)
TABLE 57 China Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 58 China Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 59 China Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 60 China Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 61 Japan Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 62 Japan Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 63 Japan Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 64 Japan Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 65 India Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 66 India Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 67 India Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 68 India Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 69 South Korea Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 70 South Korea Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 71 South Korea Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 72 South Korea Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 73 South East Asia Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 74 South East Asia Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 75 South East Asia Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 76 South East Asia Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 77 Rest of Asia Pacific Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 78 Rest of Asia Pacific Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 79 Rest of Asia Pacific Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 80 Rest of Asia Pacific Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 81 Latin America Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 82 Latin America Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 83 Latin America Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 84 Latin America Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 85 Latin America Human Insulin Market, by Country, 2017-2030 (US$ Bn)
TABLE 86 Brazil Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 87 Brazil Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 88 Brazil Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 89 Brazil Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 90 Mexico Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 91 Mexico Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 92 Mexico Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 93 Mexico Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 94 Rest of Latin America Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 95 Rest of Latin America Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 96 Rest of Latin America Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 97 Rest of Latin America Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 98 Middle East and Africa Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 99 Middle East and Africa Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 100 Middle East and Africa Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 101 Middle East and Africa Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 102 Middle East and Africa Human Insulin Market, by Country, 2017-2030 (US$ Bn)
TABLE 103 GCC Countries Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 104 GCC Countries Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 105 GCC Countries Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 106 GCC Countries Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 107 South Africa Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 108 South Africa Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 109 South Africa Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 110 South Africa Human Insulin Market, by Brand, 2017-2030 (US$ Bn)
TABLE 111 Rest of Middle East and Africa Human Insulin Market, by Product Type, 2017-2030 (US$ Bn)
TABLE 112 Rest of Middle East and Africa Human Insulin Market, by Drugs, 2017-2030 (US$ Bn)
TABLE 113 Rest of Middle East and Africa Human Insulin Market, by Delivery Devices, 2017-2030 (US$ Bn)
TABLE 114 Rest of Middle East and Africa Human Insulin Market, by Brand, 2017-2030 (US$ Bn)